ARDEN HILLS, Minn., March 26, 2014 /PRNewswire-iReach/ -- Galil Medical, the global leader in interventional oncology cryotherapy treatments, announced the launch of its latest prospective clinical research study, SOLSTICE (Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation).
The SOLSTICE Clinical Study is the largest multi-center prospective trial focused on the clinical use and effectiveness of cryotherapy treatments for patients with primary cancer lesions that have metastasized to the lung. The study calls for two years of follow up, with a projected enrollment of approximately 125 patients. This study follows on Galil Medical's successful ECLIPSE (Evaluating Cryoablation of Metastatic Lung/Pleura Tumors in Patients - Safety and Efficacy) clinical research study, which reported on 40 subjects in 2013 and is continuing in its patient follow-up stage.
Matthew Callstrom, M.D., Ph.D., Mayo Clinic, Rochester, MN and Thierry de Baere, M.D., Institut Gustave Roussy, Paris France will serve as the trial lead investigators.
Dr. de Baere commented, "My colleagues and I are pleased that we are a part of the SOLSTICE study. Following our experience with the ECLIPSE trial we look forward to better understanding the role cryoablation can play in our clinical practice and the management of lung metastasis."
"We are thrilled that many of the leading oncology institutions across the U.S. and Europe are participating in this milestone clinical trial focused on treating a patient population that we believe will benefit from cryoablation solutions" stated Martin J. Emerson, President and CEO of Galil Medical. "SOLSTICE, as well as our other clinical studies and active R&D pipeline, will further cement that Galil is the only company in the world solely committed to advancing cryotherapy over a broad range of applications and indications," Emerson continued.
For a listing of all the sites participating in the SOLSTICE study, along with further information regarding the SOLSTICE and ECLIPSE studies, as well as other clinical studies please visit www.clinicaltrials.gov.
Galil Medical continues to invest heavily in both new product innovations and clinical research. Currently, the company has eight active clinical research studies underway in the kidney, lung, bone, pain and prostate arenas in the U.S., Canada and Europe.
About Galil Medical Galil Medical is a global leader in delivering innovative cryotherapy solutions. The company is addressing patient conditions across multiple physician specialties; treatment areas include conditions affecting bone, kidney, liver, lung and prostate, as well as targeted pain and nerve applications. Company offices are located in Arden Hills, Minnesota and Yokneam, Israel. Shareholders include Thomas, McNerney & Partners, The Vertical Group, and Investor Growth Capital.
Martin J. Emerson
President and CEO
Maria Plentl, MSN
Senior Director, Global Clinical Research
Media Contact: Martin J. Emerson, Galil Medical, 651-287-5050, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Galil Medical